Tech Licensing
- Korean Biotech at BIO 2026: Kangstem Courts a Partner as Data Nears
Korean drug developers pushed partnering deals at BIO USA 2026, with Kangstem Biotech awaiting late-July Phase 2 data and G2G Bio fresh off its KOSDAQ debut.
Korean drug developers pushed partnering deals at BIO USA 2026, with Kangstem Biotech awaiting late-July Phase 2 data and G2G Bio fresh off its KOSDAQ debut.